HDAC Inhibitors, Alone Or In Combination With PI3K Inhibitors, For Treating Non-Hodgkin's Lymphoma
AssigneeAcetylon Pharmaceuticals, Inc.
InventorsSteven Norman Quayle, Simon Stewart Jones
Life of this patent
Estimating the term…
Abstract
The invention relates to HDAC inhibitors, or combinations comprising an HDAC inhibitor and a PI3K inhibitor for the treatment of non-hodgkin's lymphoma in a subject in need thereof. Also provided herein are methods for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of an HDAC inhibitor, or a combination comprising an HDAC inhibitor and a PI3K inhibitor.
Claims25
A method for treating non-hodgkin's lymphoma in a subject in need thereof comprising administering to the subject a therapeutically effective amount of a histone deacetylase 6 (HDAC6) specific inhibitor.
A pharmaceutical combination for treating non-hodgkin's lymphoma comprising a therapeutically effective amount of a histone deacetylase 6 (HDAC6) specific inhibitor or a pharmaceutically acceptable salt thereof, and a phosphatidylinositide 3-kinase (PI3K) inhibitor or a pharmaceutically acceptable salt thereof.
A method for decreasing cell viability of cancer cells by administering a histone deacetylase (HDAC) inhibitor, or a combination comprising a histone deacetylase (HDAC) inhibitor and a phosphatidylinositide 3-kinase (PI3K) inhibitor.
A method for synergistically increasing apoptosis of cancer cells by administering a combination comprising a histone deacetylase (HDAC) inhibitor and a phosphatidylinositide 3-kinase (PI3K) inhibitor.
A method for decreasing cell proliferation of cancer cells by administering a combination comprising a histone deacetylase (HDAC) inhibitor and a phosphatidylinositide 3-kinase (PI3K) inhibitor.
A method for reducing tumor growth by administering a combination comprising a histone deacetylase (HDAC) inhibitor and a phosphatidylinositide 3-kinase (PI3K) inhibitor.
A method for suppressing Myc expression by administering a combination comprising a histone deacetylase (HDAC) inhibitor and a phosphatidylinositide 3-kinase (PI3K) inhibitor.
Dependencies are inferred from the claim text.